The deal is part of a wider collaboration between the companies to develop molecular diagnostic tests using their respective platforms.
The company is in talks with potential partners in the US and China to validate the assay on clinical samples and deploy it at a large scale.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
The Broad Institute spinout will develop its CRISPR-based Sherlock platform for battlefield-ready diagnostics for infectious disease agents.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.
The companies also launched an early-access program for their first CRISPR-Chip-based product, the Genome Sensor.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.